|Articles|March 3, 2017
Frost & Sullivan Reveal Asia as Ideal Trial Destination
Frost & Sullivan have released a whitepaper, with Asia Pacific specialist CRO Novotech, revealing that Asia is becoming an ideal destination for clinical trials.
Advertisement
Frost & Sullivan have released a whitepaper, with Asia Pacific specialist CRO Novotech, revealing that Asia is becoming an ideal destination for clinical trials. The report states that this result is due to vast treatment-naive patient pools, clinical infrastructure and low operational costs.
Read the full report
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
2
Generative AI Transforms Clinical Study Report Development
3
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
4
Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
